Noopur Raje, MD, on bb21217 Data in R/R Multiple Myeloma

Video

The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.

This content originally appeared on our sister site, OncLive.

Investigators evaluated the BCMA-targeted chimeric antigen cell receptor (CAR T-cell) therapy bb21217 in patients with relapsed/refractory multiple myeloma in the phase 1 CRB-402 trial (NCT03274219).

Updated data demonstrated an overall response rate (ORR) of around 80% and rates were similar among patients who received prior treatment with a PI3K inhibitor. ORR was over 80% at the highest dose of bb21217 of 450 × 106 CAR+ T cells.

OncLive spoke with Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, to learn more about the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Regarding toxicity, no new safety signals were seen, though central nervous system toxicity was observed at grades 1 and 2, Raje noted. These toxicity findings were similar to findings reported with the use of idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel; Carvykti), Raje concluded.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Damien Maura, PhD, a senior scientist at Voyager Therapeutics
Rajeev Sivasankaran, PhD, vice president of neuroscience at Voyager Therapeutics
Sven Moller-Tank, PhD, a senior director at Regeneron
© 2025 MJH Life Sciences

All rights reserved.